Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

BCLI opened at $1.60 on Friday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89. The company has a market capitalization of $9.12 million, a P/E ratio of -0.33 and a beta of 0.26. The stock has a fifty day moving average of $1.98 and a 200-day moving average of $2.46.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.